Pharmaceutical Exports Ireland 2026 Market Overview & Trends

Ireland's pharmaceutical export value reached a five-year high of $26.36 billion in 2024. While the export value increased by over 15% compared to 2023, the total quantity exported actually decreased to 126.9 million units. This trend suggests a significant shift toward higher-value pharmaceutical products or a substantial increase in unit pricing within the global market.

The United States is the dominant destination for Irish pharmaceutical exports, with an import value of $10.1 billion in 2024. Germany ($3.33B) and the Netherlands ($2.09B) follow as the largest European partners. The data highlights Ireland's strategic reliance on the US market while maintaining a strong footprint across major EU economies like Belgium and Italy.

The United States and China represent the most significant growth opportunities, with rates of 82.4% and 40.2% respectively. While the Netherlands and Spain also show positive momentum, the United Kingdom saw a marginal decline of -1.75%, indicating a strategic pivot toward larger, high-growth international markets outside of the immediate neighboring region.

Product category HS 300490 (Medicaments for retail sale) is the cornerstone of Ireland's exports, valued at $24.04 billion in 2024. Other significant categories include corticosteroid-based medicaments (HS 300432) at $1.12 billion and antibiotics (HS 300420) at $607 million, demonstrating a specialized focus on finished therapeutic products for retail distribution.